This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.
Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries.
Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data-including population surveys, cohort studies, disease registries, administrative health data, and vital statistics-contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.
This Monograph provides the general respiratory physician with a working reference based on the latest literature and expert opinion. The initial chapter provides a contemporaneous global perspective of the epidemiology of occupational and environmental lung diseases in an ever-evolving landscape. The book then goes on to consider specific occupational lung diseases. Each chapters has a clear clinical focus and considers: key questions to ask in the history; appropriate investigations to undertake; differential diagnoses; and management. Controversies or diagnostic conundrums encountered in the clinic are also considered, and further chapters are more broadly centred on the non-workplace environment; specifically, the respiratory symptoms and diseases associated with both the outdoor and indoor environments.
Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models. The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development. - Explores recent perspectives and challenges regarding the management and diagnosis of chronic respiratory diseases - Provides insights into how advanced drug delivery systems can be effectively formulated and delivered for the management of various pulmonary diseases - Includes the most recent information on diagnostic methods and treatment strategies using controlled drug delivery systems (including nanotechnology)
Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.
This handy, accessible single volume presents useful clinical information to expose the pathophysiology underlying major pulmonary diseases, and traces the steps of treatment, from establishing diagnosis to managing therapy. Contains more than 400 summary tables, radiographs, pathology specimens, and other illustrations that encapsulate information and highlight key points! A suggested reading list accompanies each chapter to facilitate further study! Written by over 55 internationally recognized experts who provide personal experiences, observations, and review statements, and recommend action based on their expertise dealing with patients, Medical Management of Pulmonary Diseases assesses new, efficient, cost-effective technologies for asthma and for the delivery of oxygen therapy evaluates new directions in the diagnosis and treatment of cystic fibrosis, lung cancer, occupational lung diseases, and diffuse interstitial lung disease describes the anatomy and physiology of the respiratory tract and includes examples of abnormalities drawn from common respiratory diseases discusses standard therapies for most pulmonary disease patients as well as targeted management for specific cases addresses common diagnostic and treatment dilemmas and suggests helpful algorithms for care spotlights asthma, chronic obstructive pulmonary disease, sleep-disordered breathing, tuberculosis, and other conditions that warrant careful management follows the progression of lung cancer from initial diagnosis through staging, and explores individualized therapy options considers special environments that may contribute to respiratory symptoms details the effect pregnancy and surgery have on pulmonary disease and more! Medical Management of Pulmonary Diseases serves as an excellent user-friendly guide ideal for primary care, internal medicine, and family practice physicians; pulmonologists and pulmonary disease specialists; clinical allergists; immunologists; respiratory therapists; thoracic surgeons; physiologists; and medical school students in these disciplines.
This Monograph provides expert clinical guidance on these difficult diseases, which will be helpful to both respiratory and nonrespiratory physicians alike. The initial chapters consider diagnostic issues, pulmonary function tests and techniques that are currently in development. The book then goes on to cover a variety of pulmonary manifestations of very different disease entities, such as connective tissue diseases, systemic vasculitis and much more.
This text presents a detailed overview of the principal radiologic and pathologic findings of the most common pulmonary diseases. Its primary radiologic emphasis is on the appearance of the diseases and abnormalities. The goal is to offer the radiologist a greater appreciation of the patterns and distribution of the histopathologic abnormalities as shown on the imaging studies, and the pulmonary pathologist better understanding of the radiologic findings. The text features radiologic-pathologic correlation throughout and a strong emphasis on high-resolution CT, which generally provides the best depiction of anatomic features. Reviewers praised the concise and succinct narrative style of the first edition.
